Hepatitis C virus replicons: potential role for drug development


The development of causal therapies depends on the availability of systems to determine the inhibitory capacity of a compound. As viruses are obligate intracellular parasites, the efficacy of an antiviral drug is usually evaluated in a cell-culture system. Unfortunately, the hepatitis C virus, the principal causative agent of acute and chronic liver disease, cannot be propagated efficiently in the laboratory. However, the recent development of a replicon system opens up an encouraging possibility for drug discovery.

DOI: 10.1038/nrd942


Citations per Year

99 Citations

Semantic Scholar estimates that this publication has 99 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Bartenschlager2002HepatitisCV, title={Hepatitis C virus replicons: potential role for drug development}, author={Ralf Bartenschlager}, journal={Nature Reviews Drug Discovery}, year={2002}, volume={1}, pages={911-916} }